(Reuters) – A group of attorneys general from U.S. states and territories sued 26 manufacturers of dermatology drugs on Wednesday, accusing them of price fixing and other violations of antitrust law, the third such lawsuit since 2016.

This lawsuit focuses on 80 topical generic drugs, including creams, gels and ointments, which have billions in dollars of U.S. sales. It accuses Novartis unit Sandoz, Teva generic unit Actavis, Mylan Inc, Pfizer and other companies of breaking antitrust law by dividing up markets and rigging bids, according to statements from the attorneys general.